Flowers for Algernon: How metacognition affects quality of life in schizophrenia. Structural equation modeling with the FACE-SZ cohort.
Comprehensive Psychiatry. 2025-10-01; 142: 152622
DOI: 10.1016/j.comppsych.2025.152622
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/11909
Frileux S(1), Faivre N(2), Urbach M(3), Vidal N(4), Bottemanne H(5), Berna F(6),
Belmonte C(7), Boyer L(7), Capdevielle D(8), Clauss J(6), Chéreau I(9), D’Amato
T(10), Dubertret C(11), Dubreucq J(12), Fond G(13), Leigner S(12), Llorca PM(9),
Mallet J(14), Misdrahi D(15), Pignon B(16), Rey R(17), Schürhoff F(16), Tessier
A(15); List of FondaMental Advanced Center of Expertise (FACE-SZ) collaborators;
Passerieux C(35), Brunet-Gouet E(3), Roux P(36).
Collaborators: Aouizerate B(18), Barteau V(19), Bensalem S(19), Berna F(20),
Blanc O(21), Bourguignon E(22), Boyer L(23), Capdevielle D(24), Chéreau I(21),
Chesnoy-Servanin G(25), D’Amato T(25), Deloge A(26), Denizot H(21), Dorey
JM(25), Dubertret C(27), Dubreucq J(28), Esselin S(29), Faget C(30), Fluttaz
C(28), Fond G(23), Gabayet F(28), Godin O(19), Haffen E(31), Honciuc RM(21),
Jarroir M(29), Lacelle D(21), Lançon C(30), Laouamri H(19), Leboyer M(32),
Llorca PM(33), Mallet J(27), Metairie E(30), Misdrahi D(26), Passerieux C(29),
Petrucci J(22), Peri P(30), Pignon B(22), Pires S(21), Portalier C(27), Rey
R(25), Roman C(28), Schürhoff F(32), Souryis K(19), Szöke A(22), Urbach M(29),
Vaillant F(30), Vehier A(25), Vidailhet P(34), Vilà E(26), Wahiche G(22), Yazbek
H(24), Zinetti-Bertschy A(34).
Author information:
(1)FondaMental Foundation, Créteil, France; Centre Hospitalier de Versailles,
Service Universitaire de Psychiatrie d’Adultes et d’Addictologie, Le Chesnay,
France; Université Versailles Saint-Quentin-en-Yvelines, UFR Santé Simone-Veil,
Montigny-Le-Bretonneux, France; MOODS Team, INSERM 1018, CESP, Villejuif,
France. Electronic address: .
(2)Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LPNC, Grenoble, France.
(3)FondaMental Foundation, Créteil, France; Centre Hospitalier de Versailles,
Service Universitaire de Psychiatrie d’Adultes et d’Addictologie, Le Chesnay,
France; MOODS Team, INSERM 1018, CESP, Villejuif, France.
(4)Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie
d’Adultes et d’Addictologie, Le Chesnay, France; MOODS Team, INSERM 1018, CESP,
Villejuif, France.
(5)Department of Psychiatry, Bicêtre Hospital, Mood Center Paris Saclay, DMU
Neurosciences, Paris-Saclay University, Assistance Publique-Hôpitaux de Paris
(AP-HP), Kremlin-Bicêtre, France; MOODS Team, INSERM 1018, CESP (Centre de
Recherche en Epidémiologie et Santé des Populations), Université Paris-Saclay,
Faculté de Médecine Paris-Saclay, Kremlin Bicêtre, France.
(6)FondaMental Foundation, Créteil, France; University Hospitals of Strasbourg,
Department of Psychiatry, France; University of Strasbourg, Inserm U1114,
Strasbourg, France.
(7)FondaMental Foundation, Créteil, France; University Department of Adult
Psychiatry, Hospital La Colombière, CHU Montpellier, France.
(8)FondaMental Foundation, Créteil, France; University Department of Adult
Psychiatry, Hospital La Colombière, CHU Montpellier, France; Institute of
Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier,
France.
(9)FondaMental Foundation, Créteil, France; CHU Clermont-Ferrand, Service of
Psychiatry B, University of Clermont Auvergne, Clermont-Ferrand, France.
(10)FondaMental Foundation, Créteil, France; INSERM, U1028, France; CNRS,
UMR5292, France; University Lyon 1, France.
(11)FondaMental Foundation, Créteil, France; Inserm UMR1266, Institute of
Psychiatry and Neuroscience of Paris, University Paris Descartes, France;
Université Paris Diderot, Sorbonne Paris Cité, Faculty of Medicine, France.
(12)FondaMental Foundation, Créteil, France; Grenoble Alpes University, Inserm
U1216, CHU Grenoble Alpes, Grenoble Institute of Neurosciences, Grenoble,
France.
(13)FondaMental Foundation, Créteil, France; Marseille University Hospital,
Aix-Marseille Univ, School of Medicine – La Timone Medical Campus, EA 3279:
Department of Epidemiology and Health Economics, 27 Boulevard Jean Moulin, 13005
Marseille, France.
(14)FondaMental Foundation, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, France; Inserm UMR1266, Institute of
Psychiatry and Neuroscience of Paris, University Paris Descartes, France;
Université Paris Diderot, Sorbonne Paris Cité, Faculty of Medicine, France.
(15)FondaMental Foundation, Créteil, France; Department of Universitary and
General Psychiatry, Charles Perrens Hospital, University of Bordeaux, Aquitaine
Institute for Cognitive and Integrative Neuroscience (CNRS UMR 5287-INCIA,
ECOPSY), France; University of Paris-Est-Créteil (UPEC), AP-HP, Hôpitaux
Universitaires « H. Mondor », DMU IMPACT, INSERM, France.
(16)FondaMental Foundation, Créteil, France; IMRB, Translational
Neuropsychiatry, Fondation FondaMental, F-94010 Créteil, France.
(17)FondaMental Foundation, Créteil, France; Le Vinatier Hospital, Schizophrenia
Expert Centre, Bron F-69500, France; INSERM, U1028, France; CNRS, UMR5292,
France; University Lyon 1, France; Lyon Neuroscience Research Center, PSYR2
Team, Lyon F-69000, France.
(18)Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux,
France; Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286),
University of Bordeaux, France.
(19)FACE-SZ Data Coordinating Center (Fondation FondaMental), France.
(20)Strasbourg University Hospital, University of Strasbourg, INSERM U1114,
Federation of Translational Psychiatry, Strasbourg, France; FACE-SZ Clinical
Coordinating Center (Fondation FondaMental), France.
(21)CHU Clermont-Ferrand, Department of Psychiatry (Service de Psychatrie B),
University of Clermont Auvergne, Clermont-Ferrand, France.
(22)AP-HP, INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Centre Expert
Schizophrénie, Pôle de Psychiatrie et d’Addictologie des Hôpitaux Universitaires
Henri Mondor, Paris Est University, 40 rue de Mesly, 94000 Créteil, France.
(23)AP-HM, la Conception Hospital, Aix-Marseille Univ, School of medicine La
Timone Medical Campus, EA 3279: CEReSS Health Service Research, France.
(24)University Department of Adult Psychiatry, La Colombiere Hospital, CHU
Montpellier, University of Montpellier 1, Inserm 1061, Montpellier, France.
(25)University Claude Bernard Lyon 1, Le Vinatier Hospital Pole Est BP 300 3995
bd Pinel, 69678 Bron Cedex, France.
(26)Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux,
France; University of Bordeaux, CNRS UMR 5287-INCIA, Bordeaux, France.
(27)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
UMR1266, Institute of Psychiatry and Neurosciences of Paris, University Paris
Descartes, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine,
France.
(28)Psychosocial Rehabilitation Reference Center, Alpes Isère Hospital,
Grenoble, France.
(29)University of Paris-Saclay, University of Versailles
Saint-Quentin-En-Yvelines, 94807 Villejuif, France.
(30)Department of Psychiatry (AP-HM), Sainte-Marguerite University Hospital,
Marseille, France.
(31)FACE-SZ Clinical Coordinating Center (Fondation FondaMental), France.
(32)AP-HP, INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Centre Expert
Schizophrénie, Pôle de Psychiatrie et d’Addictologie des Hôpitaux Universitaires
Henri Mondor, Paris Est University, 40 rue de Mesly, 94000 Créteil, France;
FACE-SZ Clinical Coordinating Center (Fondation FondaMental), France.
(33)CHU Clermont-Ferrand, Department of Psychiatry (Service de Psychatrie B),
University of Clermont Auvergne, Clermont-Ferrand, France; FACE-SZ Clinical
Coordinating Center (Fondation FondaMental), France.
(34)Strasbourg University Hospital, University of Strasbourg, INSERM U1114,
Federation of Translational Psychiatry, Strasbourg, France.
(35)FondaMental Foundation, Créteil, France; Centre Hospitalier de Versailles,
Service Universitaire de Psychiatrie d’Adultes et d’Addictologie, Le Chesnay,
France; Université Versailles Saint-Quentin-en-Yvelines, UFR Santé Simone-Veil,
Montigny-Le-Bretonneux, France.
(36)FondaMental Foundation, Créteil, France; Centre Hospitalier de Versailles,
Service Universitaire de Psychiatrie d’Adultes et d’Addictologie, Le Chesnay,
France; Université Versailles Saint-Quentin-en-Yvelines, UFR Santé Simone-Veil,
Montigny-Le-Bretonneux, France; MOODS Team, INSERM 1018, CESP, Villejuif,
France.
BACKGROUND AND HYPOTHESIS: We examined the association between metacognitive
performance, functioning, and quality of life (QoL) in schizophrenia using
structural equation model analyses.
STUDY DESIGN: A sample of 249 participants was assessed for symptoms,
functioning, QoL, and both objective and subjective cognitive performance.
Metacognitive performance was defined as the adequation between objective and
subjective measures of cognitive performance.
STUDY RESULTS: Our model showed an excellent fit (CFI = 0.981;
RMSEA = 0.014-0.081) and explained 53.3 % of the variance in functioning and
50.3 % in QoL. Metacognitive performance was not significantly associated with
functioning but showed a negative association with QoL (β = -0.383, p